186 related articles for article (PubMed ID: 35022522)
1. Exploring the oncogenic and therapeutic target potential of the MYB-TYK2 fusion gene in B-cell acute lymphoblastic leukemia.
Shirazi PT; Eadie LN; Heatley SL; Page EC; François M; Hughes TP; Yeung D; White DL
Cancer Gene Ther; 2022 Aug; 29(8-9):1140-1152. PubMed ID: 35022522
[TBL] [Abstract][Full Text] [Related]
2. Constitutive JAK/STAT signaling is the primary mechanism of resistance to JAKi in TYK2-rearranged acute lymphoblastic leukemia.
Tavakoli Shirazi P; Eadie LN; Page EC; Heatley SL; Bruning JB; White DL
Cancer Lett; 2021 Aug; 512():28-37. PubMed ID: 33971281
[TBL] [Abstract][Full Text] [Related]
3. TYK2-STAT1-BCL2 pathway dependence in T-cell acute lymphoblastic leukemia.
Sanda T; Tyner JW; Gutierrez A; Ngo VN; Glover J; Chang BH; Yost A; Ma W; Fleischman AG; Zhou W; Yang Y; Kleppe M; Ahn Y; Tatarek J; Kelliher MA; Neuberg DS; Levine RL; Moriggl R; Müller M; Gray NS; Jamieson CH; Weng AP; Staudt LM; Druker BJ; Look AT
Cancer Discov; 2013 May; 3(5):564-77. PubMed ID: 23471820
[TBL] [Abstract][Full Text] [Related]
4. Anti-adult T‑cell leukemia/lymphoma activity of cerdulatinib, a dual SYK/JAK kinase inhibitor.
Ishikawa C; Senba M; Mori N
Int J Oncol; 2018 Oct; 53(4):1681-1690. PubMed ID: 30066853
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the in vitro and in vivo efficacy of the JAK inhibitor AZD1480 against JAK-mutated acute lymphoblastic leukemia.
Suryani S; Bracken LS; Harvey RC; Sia KC; Carol H; Chen IM; Evans K; Dietrich PA; Roberts KG; Kurmasheva RT; Billups CA; Mullighan CG; Willman CL; Loh ML; Hunger SP; Houghton PJ; Smith MA; Lock RB
Mol Cancer Ther; 2015 Feb; 14(2):364-74. PubMed ID: 25504635
[TBL] [Abstract][Full Text] [Related]
6. JAK kinase inhibitors for the treatment of acute lymphoblastic leukemia.
Degryse S; Cools J
J Hematol Oncol; 2015 Jul; 8():91. PubMed ID: 26208852
[TBL] [Abstract][Full Text] [Related]
7. Oncogenic TYK2 P760L kinase is effectively targeted by combinatorial TYK2, mTOR and CDK4/6 kinase blockade.
Woess K; Macho-Maschler S; Van Ingen Schenau DS; Butler M; Lassnig C; Valcanover D; Poelzl A; Meissl K; Maurer B; Brandstoetter T; Vogl C; Koren A; Kubicek S; Orlova A; Moriggl R; Strobl B; Sexl V; Van Leeuwen FN; Kuiper RP; Mueller M
Haematologica; 2023 Apr; 108(4):993-1005. PubMed ID: 35021603
[TBL] [Abstract][Full Text] [Related]
8. Oncogenic role and therapeutic targeting of ABL-class and JAK-STAT activating kinase alterations in Ph-like ALL.
Roberts KG; Yang YL; Payne-Turner D; Lin W; Files JK; Dickerson K; Gu Z; Taunton J; Janke LJ; Chen T; Loh ML; Hunger SP; Mullighan CG
Blood Adv; 2017 Sep; 1(20):1657-1671. PubMed ID: 29296813
[TBL] [Abstract][Full Text] [Related]
9. Tyrosine kinase 2 - Surveillant of tumours and bona fide oncogene.
Leitner NR; Witalisz-Siepracka A; Strobl B; Müller M
Cytokine; 2017 Jan; 89():209-218. PubMed ID: 26631911
[TBL] [Abstract][Full Text] [Related]
10. Germline activating TYK2 mutations in pediatric patients with two primary acute lymphoblastic leukemia occurrences.
Waanders E; Scheijen B; Jongmans MC; Venselaar H; van Reijmersdal SV; van Dijk AH; Pastorczak A; Weren RD; van der Schoot CE; van de Vorst M; Sonneveld E; Hoogerbrugge N; van der Velden VH; Gruhn B; Hoogerbrugge PM; van Dongen JJ; Geurts van Kessel A; van Leeuwen FN; Kuiper RP
Leukemia; 2017 Apr; 31(4):821-828. PubMed ID: 27733777
[TBL] [Abstract][Full Text] [Related]
11. JAK Inhibitors for Treatment of Psoriasis: Focus on Selective TYK2 Inhibitors.
Nogueira M; Puig L; Torres T
Drugs; 2020 Mar; 80(4):341-352. PubMed ID: 32020553
[TBL] [Abstract][Full Text] [Related]
12. Anti-leukaemic activity of the TYK2 selective inhibitor NDI-031301 in T-cell acute lymphoblastic leukaemia.
Akahane K; Li Z; Etchin J; Berezovskaya A; Gjini E; Masse CE; Miao W; Rocnik J; Kapeller R; Greenwood JR; Tiv H; Sanda T; Weinstock DM; Look AT
Br J Haematol; 2017 Apr; 177(2):271-282. PubMed ID: 28295194
[TBL] [Abstract][Full Text] [Related]
13. TYK2 Variants in B-Acute Lymphoblastic Leukaemia.
Turrubiartes-Martínez E; Bodega-Mayor I; Delgado-Wicke P; Molina-Jiménez F; Casique-Aguirre D; González-Andrade M; Rapado I; Camós M; Díaz-de-Heredia C; Barragán E; Ramírez-Orellana M; Aguado B; Figuera Á; Martínez-López J; Fernández-Ruiz E
Genes (Basel); 2020 Nov; 11(12):. PubMed ID: 33260630
[TBL] [Abstract][Full Text] [Related]
14. Tyrosine kinase 2 and Janus kinase‒signal transducer and activator of transcription signaling and inhibition in plaque psoriasis.
Krueger JG; McInnes IB; Blauvelt A
J Am Acad Dermatol; 2022 Jan; 86(1):148-157. PubMed ID: 34224773
[TBL] [Abstract][Full Text] [Related]
15. Low incidence of ABL-class and JAK-STAT signaling pathway alterations in uniformly treated pediatric and adult B-cell acute lymphoblastic leukemia patients using MRD risk-directed approach - a population-based study.
Norvilas R; Dirse V; Semaskeviciene R; Mickeviciute O; Gineikiene E; Stoskus M; Vaitkeviciene G; Rascon J; Griskevicius L
BMC Cancer; 2021 Mar; 21(1):326. PubMed ID: 33781217
[TBL] [Abstract][Full Text] [Related]
16. Connectivity mapping identifies HDAC inhibitors for the treatment of t(4;11)-positive infant acute lymphoblastic leukemia.
Stumpel DJ; Schneider P; Seslija L; Osaki H; Williams O; Pieters R; Stam RW
Leukemia; 2012 Apr; 26(4):682-92. PubMed ID: 22015773
[TBL] [Abstract][Full Text] [Related]
17. Selectivity Profile of the Tyrosine Kinase 2 Inhibitor Deucravacitinib Compared with Janus Kinase 1/2/3 Inhibitors.
Chimalakonda A; Burke J; Cheng L; Catlett I; Tagen M; Zhao Q; Patel A; Shen J; Girgis IG; Banerjee S; Throup J
Dermatol Ther (Heidelb); 2021 Oct; 11(5):1763-1776. PubMed ID: 34471993
[TBL] [Abstract][Full Text] [Related]
18. Tyk2 is dispensable for induction of myeloproliferative disease by mutant FLT3.
Nakajima H; Shibata F; Kumagai H; Shimoda K; Kitamura T
Int J Hematol; 2006 Jul; 84(1):54-9. PubMed ID: 16867903
[TBL] [Abstract][Full Text] [Related]
19. Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia.
Roberts KG; Li Y; Payne-Turner D; Harvey RC; Yang YL; Pei D; McCastlain K; Ding L; Lu C; Song G; Ma J; Becksfort J; Rusch M; Chen SC; Easton J; Cheng J; Boggs K; Santiago-Morales N; Iacobucci I; Fulton RS; Wen J; Valentine M; Cheng C; Paugh SW; Devidas M; Chen IM; Reshmi S; Smith A; Hedlund E; Gupta P; Nagahawatte P; Wu G; Chen X; Yergeau D; Vadodaria B; Mulder H; Winick NJ; Larsen EC; Carroll WL; Heerema NA; Carroll AJ; Grayson G; Tasian SK; Moore AS; Keller F; Frei-Jones M; Whitlock JA; Raetz EA; White DL; Hughes TP; Guidry Auvil JM; Smith MA; Marcucci G; Bloomfield CD; Mrózek K; Kohlschmidt J; Stock W; Kornblau SM; Konopleva M; Paietta E; Pui CH; Jeha S; Relling MV; Evans WE; Gerhard DS; Gastier-Foster JM; Mardis E; Wilson RK; Loh ML; Downing JR; Hunger SP; Willman CL; Zhang J; Mullighan CG
N Engl J Med; 2014 Sep; 371(11):1005-15. PubMed ID: 25207766
[TBL] [Abstract][Full Text] [Related]
20. Use of recombinant cell-permeable small peptides to modulate glucocorticoid sensitivity of acute lymphoblastic leukemia cells.
Geng CD; Vedeckis WV
Biochemistry; 2010 Oct; 49(41):8892-901. PubMed ID: 20831260
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
